MX2016008110A - Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. - Google Patents
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.Info
- Publication number
- MX2016008110A MX2016008110A MX2016008110A MX2016008110A MX2016008110A MX 2016008110 A MX2016008110 A MX 2016008110A MX 2016008110 A MX2016008110 A MX 2016008110A MX 2016008110 A MX2016008110 A MX 2016008110A MX 2016008110 A MX2016008110 A MX 2016008110A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- formula
- dlk
- inhibitors
- pyrazole derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Abstract
La presente invención proporciona compuestos de fórmula 0 y varias modalidades de los mismos, y composiciones que comprenden compuestos de fórmula 0 y varias modalidades de los mismos. (ver Fórmula) En los compuestos de fórmula 0, los grupos R1A, R1B, R1C, R1D, R2, R3, R4, R5 y R6 tienen el significado, tal como se describe en la presente descripción. La presente invención también proporciona métodos para usar compuestos de fórmula 0 y composiciones que comprenden compuestos de fórmula 0 como inhibidores de DLK y para tratar enfermedades y afecciones neurodegenerativas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2013/090153 | 2013-12-20 | ||
PCT/EP2014/078620 WO2015091889A1 (en) | 2013-12-20 | 2014-12-19 | Pyrazole derivatives and uses thereof as inhibitors of dlk |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016008110A true MX2016008110A (es) | 2016-08-19 |
Family
ID=52278622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016008110A MX2016008110A (es) | 2013-12-20 | 2014-05-28 | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US9365583B2 (es) |
EP (1) | EP3083599B1 (es) |
JP (1) | JP6228310B2 (es) |
CN (1) | CN105939997B (es) |
AR (1) | AR098853A1 (es) |
CA (1) | CA2934011A1 (es) |
HK (1) | HK1226053A1 (es) |
MX (1) | MX2016008110A (es) |
RU (1) | RU2016128368A (es) |
TW (1) | TW201609692A (es) |
WO (1) | WO2015091889A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2852584B1 (en) * | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
BR112015016395A2 (pt) * | 2013-01-18 | 2017-07-11 | Hoffmann La Roche | pirazóis 3-substituídos e uso como inibidores de dlk |
KR20160002850A (ko) | 2013-05-01 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도 |
EP3503889A1 (en) * | 2016-08-29 | 2019-07-03 | Board Of Regents, The University Of Texas System | Inhibitors of dual leucine ziper (dlk) kinase for the treatment of disease |
US10093664B2 (en) * | 2016-12-08 | 2018-10-09 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
WO2018136437A2 (en) | 2017-01-17 | 2018-07-26 | Tesaro, Inc. | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
KR20200030558A (ko) | 2017-07-14 | 2020-03-20 | 에프. 호프만-라 로슈 아게 | 이환형 케톤 화합물 및 이의 사용 방법 |
CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CA3078653A1 (en) | 2017-10-11 | 2019-04-18 | F. Hoffmann-La Roche Ag | Bicyclic compounds for use as rip1 kinase inhibitors |
CR20200168A (es) | 2017-10-31 | 2020-07-12 | Hoffmann La Roche | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos |
CN112074519A (zh) | 2018-04-20 | 2020-12-11 | 豪夫迈·罗氏有限公司 | 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征(ibs)的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物 |
WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
JP2022516651A (ja) | 2019-01-11 | 2022-03-01 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 二環式ピロロトリアゾールケトン化合物及びその使用方法 |
US11560366B2 (en) | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
CA3229861A1 (en) * | 2021-09-01 | 2023-03-09 | John F. BROGNARD | Mixed lineage kinase inhibitors and methods of use |
WO2023097230A1 (en) * | 2021-11-23 | 2023-06-01 | Genentech, Inc. | Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination |
WO2024073662A1 (en) * | 2022-09-30 | 2024-04-04 | Genentech, Inc. | Azole modulators of cholesterol biosynthesis and their use for promoting remyelination |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
CA2507762C (en) | 2002-12-03 | 2013-02-05 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
WO2005025511A2 (en) | 2003-09-10 | 2005-03-24 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
CN102047061A (zh) * | 2008-05-30 | 2011-05-04 | 福斯特韦勒能源股份公司 | 通过氧化燃料燃烧发电的方法和系统 |
BR112012009257A2 (pt) | 2009-10-22 | 2016-11-22 | Genentech Inc | modulação de degeneração de axônio. |
US8846909B2 (en) | 2010-05-24 | 2014-09-30 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
EP2852584B1 (en) * | 2012-05-22 | 2018-02-28 | F. Hoffmann-La Roche AG | Substituted dipyridylamines and uses thereof |
CA2875080C (en) * | 2012-06-01 | 2020-03-24 | Taisho Pharmaceutical Co., Ltd. | Prodrug of fluorine-containing amino acid |
BR112015016395A2 (pt) * | 2013-01-18 | 2017-07-11 | Hoffmann La Roche | pirazóis 3-substituídos e uso como inibidores de dlk |
PE20200447A1 (es) * | 2013-05-01 | 2020-02-28 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos |
-
2014
- 2014-05-28 MX MX2016008110A patent/MX2016008110A/es unknown
- 2014-12-19 WO PCT/EP2014/078620 patent/WO2015091889A1/en active Application Filing
- 2014-12-19 AR ARP140104786A patent/AR098853A1/es unknown
- 2014-12-19 US US14/576,890 patent/US9365583B2/en active Active
- 2014-12-19 RU RU2016128368A patent/RU2016128368A/ru unknown
- 2014-12-19 JP JP2016541483A patent/JP6228310B2/ja active Active
- 2014-12-19 EP EP14821614.6A patent/EP3083599B1/en active Active
- 2014-12-19 CN CN201480069220.8A patent/CN105939997B/zh active Active
- 2014-12-19 TW TW103144678A patent/TW201609692A/zh unknown
- 2014-12-19 CA CA2934011A patent/CA2934011A1/en not_active Abandoned
-
2016
- 2016-12-14 HK HK16114233A patent/HK1226053A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015091889A1 (en) | 2015-06-25 |
EP3083599A1 (en) | 2016-10-26 |
RU2016128368A (ru) | 2018-01-23 |
HK1226053A1 (zh) | 2017-09-22 |
JP6228310B2 (ja) | 2017-11-08 |
JP2017504605A (ja) | 2017-02-09 |
CN105939997B (zh) | 2020-01-21 |
US20150175619A1 (en) | 2015-06-25 |
TW201609692A (zh) | 2016-03-16 |
CA2934011A1 (en) | 2015-06-25 |
AR098853A1 (es) | 2016-06-15 |
US9365583B2 (en) | 2016-06-14 |
EP3083599B1 (en) | 2020-07-01 |
CN105939997A (zh) | 2016-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016008110A (es) | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. | |
MX2015009270A (es) | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). | |
GEP20217248B (en) | 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh | |
TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
TN2017000544A1 (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors | |
MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
MY192059A (en) | Heterocyclic amides as kinase inhibitors | |
EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
MX2015013481A (es) | Compuestos heterociclicos fusionados como inhibidores de proteina quinasa. | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MY194074A (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
MX2015012431A (es) | Pirrol amida como inhibidores. | |
MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
MX2015011273A (es) | Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta. | |
MX367897B (es) | Derivados de piridazinona macrociclicos. | |
MX2017003930A (es) | Derivados de aminotriazina utiles como compuestos inhibidores de la cinasa de union a tank. | |
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
GEP20196961B (en) | 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139 | |
PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
MX369952B (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. | |
MX2016003823A (es) | Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma. |